QP-Brain

Quibim

Key Features

Brain segmentation
Volume calculation
White matter hyperintensities quantification

General Information

Product name

QP-Brain

Company

Quibim

Subspeciality

Neuro

Modality

Disease targeted

Alzheimer’s Disease, Frontotemporal dementia, Mild Cognitive Impariment (MCI), Multiple Sclerosis

Main task

Not specified

Technical Specifications

Population

Patients with suspected or confirmed conditions associated with brain atrophy/white matter hyperintensities such as neurodegenerative diseases.

Patient population age

Not specified

Input

3D T1w gradient echo, T2 FLAIR

Input format

DICOM

Output

Segmentation and quantification of grey matter, white matter, and CSF and their parcellation in several anatomical subregions. Segmentation and quantification of white matter hyperintensities.

Output format

DICOM PDF

Integration

Integration in standard reading environment (PACS)

Deployment

Cloud-based

Trigger for analysis

Automatically, Right after the image acquisition

Processing time

Not specified

Regulatory Information

CE Certification

Pathway:

MDR

Class:

Class IIa

Verified by Health AI Register

FDA Certification

Pathway:

510(k) cleared

Class:

Class II

Verified by Health AI Register

Other certifications

Not specified

Market Presence

On market since

12-2023

AI Platforms

Not specified

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Subscription

Based on

Number of analyses

Evidence & Research

Peer-Reviewed Papers

Peer-Reviewed

View

Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study